Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1

A family of drug transporters: the multidrug resistance-associated proteins

Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

Schuetz, J. D., Connelly, M., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V., Kumar, A., & Fridland, A. (1999) · Nature Medicine · doi:10.1038/12487 · Cited by 575

Multidrug resistance: molecular mechanisms and clinical relevance

Ling, V. W. T. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051053 · Cited by 525

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439

Structural, mechanistic and clinical aspects of MRP1

Hipfner, D. R., Deeley, R. G., & Cole, S. P. C. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00168-6 · Cited by 412

A comparison of the biological activities of wild‐type and mutant p53

Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 410

p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.

Fan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 404

Multiple physiological functions for multidrug transporter P-glycoprotein?

Johnstone, R. W., Ruefli, A. A., & Smyth, M. J. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01493-0 · Cited by 308

p53 mutations in cancer

Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290

The extraordinary ligand binding properties of human serum albumin

Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., Notari, S., & Ascenzi, P. (2005) · IUBMB Life · doi:10.1080/15216540500404093 · Cited by 1,090

Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting

Borrero, L. J. H., & El‐Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 805

Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System

Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726

Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.

Dittmer, J. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-29 · Cited by 498

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440

NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells

Bentires‐Alj, M., Barbu, V., Fillet, M., Chariot, A., Relić, B., Jacobs, N., GIELEN, J. E., Merville, M., & Bours, V. (2003) · Oncogene · doi:10.1038/sj.onc.1206056 · Cited by 436

Transcriptional regulation of ABC drug transporters

Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 406

Gain-of-function mutant p53 in cancer progression and therapy

Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 358

Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy

Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308

Regulation of the multidrug resistance transporter P‐glycoprotein in multicellular tumor spheroids by hypoxia‐inducible factor‐1 and reactive oxygen species

Wartenberg, M., Ling, F. C., Müschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Pütz, V., Hescheler, J., & Sauer, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0358fje · Cited by 287

New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy

Mirzayans, R., Andrais, B., Scott, A., & Murray, D. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/170325 · Cited by 257

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 251

Self-assembled polyethylenimine-graft-poly(ε-caprolactone) micelles as potential dual carriers of genes and anticancer drugs

Li, Q., & Bae, Y. H. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.035 · Cited by 238

Mutant p53 in Cancer Progression and Targeted Therapies

Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 230

Drug transport proteins in the liver

Faber, K. N., Müller, M. M., & Jansen, P. L. M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00173-4 · Cited by 222

The role of the transcription factor Ets1 in carcinoma

Dittmer, J. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.010 · Cited by 213

Transcription regulation by mutant p53

Weisz, L., Oren, M., & Rotter, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207

Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

Ho, G., Moodie, F. M., & Satsangi, J. (2003) · Gut · doi:10.1136/gut.52.5.759 · Cited by 204

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202

Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance

Chen, K. G., & Sikic, B. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1590 · Cited by 197

Mutant p53 cooperates with ETS2 to promote etoposide resistancePreprint

Do, P. M., Varanasi, L., Fan, S., Li, C., Kubacka, I., Newman, V., Chauhan, K. M., Daniels, S. R., Boccetta, M., Garrett, M. R., et al. (2012) · Genes & Development · doi:10.1101/gad.181685.111 · Cited by 201

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

Fontemaggi, G., Dell’Orso, S., Trisciuoglio, D., Shay, T., Melucci, E., Fazi, F., Terrenato, I., Mottolese, M., Muti, P. C., Domany, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1669 · Cited by 195

YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins

Agostino, S. D., Sorrentino, G., Ingallina, E., Valenti, F., Ferraiuolo, M. A., Bicciato, S., Piazza, S., Strano, S., Sal, G. D., & Blandino, G. (2015) · EMBO Reports · doi:10.15252/embr.201540488 · Cited by 200

P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease

Juvale, I. I. A., Hamid, A. A. A., Halim, K. B. A., & Has, A. T. C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09777 · Cited by 215

MDR1 Genotype-Related Pharmacokinetics and Pharmacodynamics.

Sakaeda, T., Nakamura, T., & Okumura, K. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.1391 · Cited by 190

Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches

Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. Á., Ortíz-Sánchez, E., & García-Carrancá, A. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 203

Transcriptional regulators of the human multidrug resistance 1 gene: recent views

Labialle, S., Gayet, L., Marthinet, E., Rigal, D., & Baggetto, L. G. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01156-5 · Cited by 172

Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy

Prokocimer, M., Molchadsky, A., & Rotter, V. (2017) · Blood · doi:10.1182/blood-2017-02-763086 · Cited by 172

Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis

Stein, Y., Rotter, V., & Aloni-Grinstein, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246197 · Cited by 169

p53 and metabolism: from mechanism to therapeutics

Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 159

MDR1 Genotype-related Pharmacokinetics: Fact or Fiction?

Sakaeda, T. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.391 · Cited by 150

MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function

Donzelli, S., Fontemaggi, G., Fazi, F., Agostino, S. D., Padula, F., Biagioni, F., Muti, P. C., Strano, S., & Blandino, G. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.190 · Cited by 154

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53

Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells

Masciarelli, S., Fontemaggi, G., Agostino, S. D., Donzelli, S., Carcarino, E., Strano, S., & Blandino, G. (2013) · Oncogene · doi:10.1038/onc.2013.106 · Cited by 144

How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance

Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 143

Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53Preprint

Pfister, N. T., & Prives, C. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026054 · Cited by 146

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)

Tan, B. S., Tiong, K. H., Choo, H. L., Chung, F. F., Hii, L., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.191 · Cited by 138

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

Vaghari‐Tabari, M., Hassanpour, P., Sadeghsoltani, F., Malakoti, F., Alemi, F., Qujeq, D., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00348-2 · Cited by 137

Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities

Kollareddy, M., Dimitrova, E., Vallabhaneni, K. C., Chan, A., Le, T., Chauhan, K. M., Carrero, Z. I., Ramakrishnan, G., Watabe, K., Haupt, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms8389 · Cited by 127

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants

Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123

Expression of MRP4 Confers Resistance to Ganciclovir and Compromises Bystander Cell Killing

Adachi, M., Sampath, J., Lan, L.-B., Sun, D., Hargrove, P., Flatley, R. M., Tatum, A., Edwards, M. Z., Wezeman, M. J., Matherly, L. H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203262200 · Cited by 121

Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells

Ding, Z., Li, Y., Xie, X., Xie, F., Pan, F., Li, J., He, J., & Liang, H. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0828-5 · Cited by 123

The role of TP53 in acute myeloid leukemia: Challenges and opportunities

Barbosa, K., Li, S., Adams, P. D., & Deshpande, A. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22796 · Cited by 118

Cancer chemoresistance: The relationship between p53 and multidrug transporters

Bush, J., & Li, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10226 · Cited by 117

Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line

Chan, K.-T., & Lung, M. L. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0767-4 · Cited by 109

Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer

Rachagani, S., Macha, M. A., Heimann, N., Seshacharyulu, P., Haridas, D., Chugh, S., & Batra, S. K. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.020 · Cited by 107

Involvement of p53 in the Repair of DNA Double Strand Breaks: Multifaceted Roles of p53 in Homologous Recombination Repair (HRR) and Non-Homologous End Joining (NHEJ)

Menon, V., & Povirk, L. F. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_17 · Cited by 105

A Critical Dose of Doxorubicin Is Required to Alter the Gene Expression Profiles in MCF-7 Cells Acquiring Multidrug Resistance

Shang-Hsun, T., Chen, T.-M., Hsiao, H.-T., & Chen, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116747 · Cited by 110

Tumor Suppressors Having Oncogenic Functions: The Double Agents

Datta, N., Chakraborty, S., Basu, M., & Ghosh, M. K. (2020) · Cells · doi:10.3390/cells10010046 · Cited by 114

Transcriptional activities of mutant p53: When mutations are more than a loss

Kim, E. L., & Deppert, W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20271 · Cited by 102

DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53

Alam, S. K., Yadav, V. K., Bajaj, S., Datta, A., Dutta, S. K., Bhattacharyya, M., Bhattacharya, S. S., Debnath, S., Roy, S., Boardman, L. A., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.133 · Cited by 99

Degradation of mutant p53H175 protein by Zn(II) through autophagy

Garufi, A., Pucci, D., D’Orazi, V., Cirone, M., Bossi, G., Avantaggiati, M. L., & D’Orazi, G. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.217 · Cited by 97

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103

p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3

Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0336 · Cited by 96

ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma

Ceballos, M. P., Rigalli, J. P., Ceré, L. I., Semeniuk, M., Catania, V. A., & Ruiz, M. L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180105103637 · Cited by 97

Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors

Aure, M. R. R., Leivonen, S., Fleischer, T., Zhu, Q., Overgaard, J., Alsner, J., Tramm, T., Louhimo, R., Alnæs, G. I. G., Perälä, M., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-11-r126 · Cited by 93

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

Tornesello, M. L. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5448 · Cited by 105

Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function

Gurtner, A., Starace, G., Norelli, G., Piaggio, G., Sacchi, A., & Bossi, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094813 · Cited by 92

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy

Bossi, G., Marampon, F., Maor-Aloni, R., ZANI, B. M., Rotter, V., Oren, M., Strano, S., Blandino, G., & Sacchi, A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6161 · Cited by 92

Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer

Bharathiraja, P., Yadav, P., Sajid, A., Ambudkar, S. V., & Prasad, N. R. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101004 · Cited by 94

Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells

Agapova, L. S., Chernyak, B. V., Domnina, L. V., Dugina, V. B., Efimenko, A. Y., Fetisova, E. K., Ivanova, O. Y., Kalinina, N., Хромова, Н. В., Kopnin, B. P., et al. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908120031 · Cited by 88

Overcoming drug resistance by regulating nuclear receptors

Chen, T. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.008 · Cited by 88

Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy

Lazarowski, A., Lubieniecki, F. J., Camarero, S., Pomata, H. H., Bartuluchi, M., Sevlever, G. E., & Taratuto, A. L. (2004) · Pediatric Neurology · doi:10.1016/s0887-8994(03)00407-7 · Cited by 86

Synthetically lethal nanoparticles for treatment of endometrial cancer

Ebeid, K., Meng, X., Thiel, K. W., Do, A., Geary, S. M., Morris, A. S., Pham, E. L., Wongrakpanich, A., Chhonker, Y. S., Murry, D. J., et al. (2017) · Nature Nanotechnology · doi:10.1038/s41565-017-0009-7 · Cited by 82

Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma

Agostino, S. D., Valenti, F., Sacconi, A., Fontemaggi, G., Pallocca, M., Pulito, C., Ganci, F., Muti, P. C., Strano, S., & Blandino, G. (2018) · Theranostics · doi:10.7150/thno.22167 · Cited by 85

Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy

He, C., Li, L., Guan, X., Li, X., & Miao, X. (2016) · Chemotherapy · doi:10.1159/000446361 · Cited by 80

A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis

Subramanian, M., Francis, P., Bilke, S., Li, X. L., Hara, T., Lu, X., Jones, M. F., Walker, R. L., Zhu, Y. J., Pineda, M. A., et al. (2014) · Oncogene · doi:10.1038/onc.2014.46 · Cited by 79

Mutant p53 proteins bind DNA in a DNA structure-selective mode

hler, T. G. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76

Forced Expression of Heat Shock Protein 27 (Hsp27) Reverses P-Glycoprotein (ABCB1)-mediated Drug Efflux and MDR1 Gene Expression in Adriamycin-resistant Human Breast Cancer Cells

Kanagasabai, R., Krishnamurthy, K., Druhan, L. J., & Ilangovan, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.249102 · Cited by 76

Reactivation of mutant p53 by capsaicin, the major constituent of peppers

Garufi, A., Pistritto, G., Cirone, M., & D’Orazi, G. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0417-9 · Cited by 76

Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells

Junk, D. J., Vrba, L., Watts, G. S., Oshiro, M. M., Martinez, J. D., & Futscher, B. W. (2008) · Neoplasia · doi:10.1593/neo.08120 · Cited by 74

A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells

Garufi, A., Trisciuoglio, D., Porru, M., Leonetti, C., Stoppacciaro, A., D’Orazi, V., Avantaggiati, M. L., Crispini, A., Pucci, D., & D’Orazi, G. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-72 · Cited by 74

Crosstalk in cancer resistance and metastasis

Norouzi, S., Valokola, M. G., Mosaffa, F., Zirak, M. R., Zamani, P., & Behravan, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.017 · Cited by 73

Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type II

Kalo, E., Buganim, Y., Shapira, K. E., Besserglick, H., Goldfinger, N., Weisz, L., Stambolsky, P., Henis, Y. I., & Rotter, V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00374-07 · Cited by 70

Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells

Zhu, K., Chen, L., Han, X., Wang, J., & Wang, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1633 · Cited by 69

The network of P-glycoprotein and microRNAs interactions

Lopes-Rodrigues, V., Seca, H., Sousa, D., Sousa, E., Lima, R. T., & Vasconcelos, M. H. (2013) · International Journal of Cancer · doi:10.1002/ijc.28500 · Cited by 69

Importance of ABCC1 for cancer therapy and prognosis

Kunická, T., & Souček, P. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.901348 · Cited by 66

Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity

Quante, T., Otto, B., Brázdová, M., Kejnovská, I., Deppert, W., & Tolstonog, G. V. (2012) · Cell Cycle · doi:10.4161/cc.21646 · Cited by 65

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma

Zheng, T., Yin, D., Lu, Z., Wang, J., Li, Y., Chen, X., Liang, Y., Song, X., Qi, S., Sun, B., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-133 · Cited by 60

Hepatocyte Growth Factor and Inducible Nitric Oxide Synthase Are Involved in Multidrug Resistance–Induced Angiogenesis in Hepatocellular Carcinoma Cell Lines

Lasagna, N., Fantappiè, O., Solazzo, M., Morbidelli, L., Marchetti, S., Cipriani, G., Ziche, M., & Mazzanti, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2290 · Cited by 58

P53 transcriptional activities: A general overview and some thoughts

Millau, J., Bastien, N., & Drouin, R. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.06.002 · Cited by 65

Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase

Wang, X., Chen, J., Liu, Y., You, C., & Mao, Q. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1257-9 · Cited by 57

The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance

Reed, K., Hembruff, S. L., Sprowl, J. A., & Parissenti, A. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.1 · Cited by 56

Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells

Yoshikawa, K., Hamada, J., Tada, M., Kameyama, T., Nakagawa, K., Suzuki, Y., Ikawa, M., Hassan, N. M. M., Kitagawa, Y., & Moriuchi, T. (2010) · Biomedical Research · doi:10.2220/biomedres.31.401 · Cited by 55

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers

Ferraiuolo, M. A., Verduci, L., Blandino, G., & Strano, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050961 · Cited by 56

ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression

Kato, T., Fujita, Y., Nakane, K., Kojima, T., 義則, 野., Deguchi, T., & Ito, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.047 · Cited by 53

Mutant p53 and the Response to Chemotherapy and Radiation

Tchelebi, L. T., Ashamalla, H. L., & Graves, P. R. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_8 · Cited by 53

Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers

Ku, J.-L., Shin, Y.-K., Kim, D.-W., Kim, K.-H., Choi, J.-S., Hong, S.-H., Jeon, Y.-K., Kim, S.-H., Kim, H.-S., Park, J.-H., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq043 · Cited by 52

Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: A five year follow-up analysis

Mignogna, C., Staibano, S., Altieri, V. M., Rosa, G. D., Pannone, G., Santoro, A., Zamparese, R., D'Armiento, M., Rocchetti, R., Mezza, E., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-293 · Cited by 52

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53

Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50

Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1

Kim, E. L., Gunther, W. C., Yoshizato, K., Meissner, H., Zapf, S., Nüsing, R. M., Yamamoto, H., Meir, E. G. V., Deppert, W., & Giese, A. (2003) · Oncogene · doi:10.1038/sj.onc.1207155 · Cited by 50

Aberrant expression of ETS1 and ETS2 proteins in cancer

Fry, E. A., & Inoue, K. (2018) · Cancer Reports and Reviews · doi:10.15761/crr.1000151 · Cited by 52

The Rich World of p53 DNA Binding Targets: The Role of DNA Structure

Brázda, V., & Fojta, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225605 · Cited by 56

Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes

Marroni, M., Agrawal, M., Kight, K. E., Hallene, K. L., Hossain, M. A., Cucullo, L., Signorelli, K. L., Namura, S., Bingaman, W. E., & Janigro, D. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00515-3 · Cited by 49

Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progressionPreprint

Yue, X., Zhang, C., Zhao, Y., Liu, J., Lin, A. W., Tan, V. M., Drake, J. M., Liu, L., Boateng, M. N., Li, J., et al. (2017) · Genes & Development · doi:10.1101/gad.301564.117 · Cited by 50

Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells

Zhu, H., Liu, Z., Tang, L., Liu, J., Zhou, M., Xie, F., Wang, Z., Wang, Y., Shen, S., Hu, L., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.046 · Cited by 48

Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy

Wu, M., Liu, X., Jin, W., Li, Y., Li, Y., Hu, Q., Chu, P. K.-H., Tang, G., & Yuan, P. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.011 · Cited by 48

The Region 3′ to the Major Transcriptional Start Site of the MDR1 Downstream Promoter Mediates Activation by a Subset of Mutant P53 Proteins

Strauss, B. E., & Haas, M. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2781 · Cited by 33

Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants.

Nguyen, K. T., Liu, B.-Y., Ueda, K., Gottesman, M. M., Pastan, I. H., & Chin, K. (1994) · PubMed · Cited by 54

Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells

Nicoletti, M. I., Myers, T. G., Fojo, T., & Blagosklonny, M. V. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.2.375 · Cited by 5

Mutant p53 cooperates with ETS2 to promote etoposide resistancePreprint

Do, P. M., Varanasi, L., Fan, S., Li, C., Kubacka, I., Newman, V., Chauhan, K. M., Daniels, S. R., Boccetta, M., Garrett, M. R., et al. (2012) · Genes & Development · doi:10.1101/gad.181685.111 · Cited by 201

Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.

Wang, Q., & Beck, W. T. (1998) · PubMed · Cited by 112